 Steven Ahrendt
Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 3 | 2020 | 54 | 0.830 |
Why?
| | Pancreatic Neoplasms | 7 | 2022 | 721 | 0.820 |
Why?
| | Hyperglycemia | 1 | 2020 | 295 | 0.560 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2022 | 208 | 0.490 |
Why?
| | Hyperthermia, Induced | 3 | 2020 | 65 | 0.400 |
Why?
| | Cytoreduction Surgical Procedures | 2 | 2020 | 40 | 0.300 |
Why?
| | Laparoscopy | 2 | 2021 | 400 | 0.270 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 2 | 2015 | 4 | 0.240 |
Why?
| | Coelomomyces | 1 | 2023 | 1 | 0.230 |
Why?
| | Anopheles | 1 | 2023 | 13 | 0.230 |
Why?
| | Parasites | 1 | 2023 | 37 | 0.210 |
Why?
| | Pancreaticoduodenectomy | 2 | 2021 | 130 | 0.200 |
Why?
| | Nomograms | 1 | 2022 | 42 | 0.200 |
Why?
| | Pancreatectomy | 2 | 2021 | 168 | 0.190 |
Why?
| | Cystadenoma, Serous | 1 | 2020 | 17 | 0.180 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2020 | 44 | 0.170 |
Why?
| | Postoperative Complications | 2 | 2020 | 2167 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2015 | 862 | 0.160 |
Why?
| | Adenoma | 1 | 2020 | 187 | 0.160 |
Why?
| | Patient Compliance | 1 | 2021 | 524 | 0.150 |
Why?
| | Neoadjuvant Therapy | 3 | 2022 | 301 | 0.130 |
Why?
| | Appendiceal Neoplasms | 1 | 2015 | 14 | 0.130 |
Why?
| | Retrospective Studies | 6 | 2022 | 12616 | 0.130 |
Why?
| | Glucose | 1 | 2020 | 904 | 0.120 |
Why?
| | Microsporidia | 1 | 2013 | 2 | 0.110 |
Why?
| | Genome, Fungal | 1 | 2013 | 28 | 0.110 |
Why?
| | DNA, Fungal | 1 | 2013 | 69 | 0.110 |
Why?
| | Chytridiomycota | 1 | 2013 | 25 | 0.110 |
Why?
| | Sarcoma | 1 | 2013 | 137 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 1891 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1045 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 1359 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2015 | 617 | 0.080 |
Why?
| | Quality of Life | 1 | 2019 | 2391 | 0.080 |
Why?
| | Humans | 10 | 2022 | 115890 | 0.060 |
Why?
| | Survival Rate | 2 | 2021 | 1653 | 0.060 |
Why?
| | Age Factors | 2 | 2022 | 2915 | 0.060 |
Why?
| | Crustacea | 1 | 2023 | 3 | 0.060 |
Why?
| | Neoplasm Grading | 2 | 2015 | 244 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2019 | 4446 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2015 | 334 | 0.050 |
Why?
| | Larva | 1 | 2023 | 193 | 0.050 |
Why?
| | CA-19-9 Antigen | 1 | 2022 | 13 | 0.050 |
Why?
| | Aged | 4 | 2022 | 19296 | 0.050 |
Why?
| | Tumor Burden | 1 | 2022 | 261 | 0.050 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 187 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2021 | 9165 | 0.050 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2020 | 61 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 3342 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 445 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 1088 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2022 | 1177 | 0.040 |
Why?
| | Middle Aged | 4 | 2022 | 27080 | 0.040 |
Why?
| | Transcriptome | 1 | 2023 | 741 | 0.040 |
Why?
| | Comorbidity | 1 | 2022 | 1476 | 0.040 |
Why?
| | Sex Factors | 1 | 2022 | 1743 | 0.030 |
Why?
| | Male | 5 | 2022 | 56123 | 0.030 |
Why?
| | Female | 5 | 2022 | 60076 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 2015 | 104 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2015 | 193 | 0.030 |
Why?
| | Necrosis | 1 | 2015 | 211 | 0.030 |
Why?
| | Adult | 3 | 2022 | 30814 | 0.030 |
Why?
| | Carcinoma | 1 | 2015 | 200 | 0.030 |
Why?
| | Cell Wall | 1 | 2013 | 50 | 0.030 |
Why?
| | Sarcoma, Synovial | 1 | 2013 | 10 | 0.030 |
Why?
| | Mitomycin | 1 | 2013 | 27 | 0.030 |
Why?
| | Leiomyosarcoma | 1 | 2013 | 24 | 0.030 |
Why?
| | Pennsylvania | 1 | 2013 | 94 | 0.030 |
Why?
| | Liposarcoma | 1 | 2013 | 26 | 0.030 |
Why?
| | DNA Damage | 1 | 2015 | 356 | 0.030 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2013 | 43 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2015 | 1128 | 0.030 |
Why?
| | Doxorubicin | 1 | 2013 | 290 | 0.020 |
Why?
| | Cisplatin | 1 | 2013 | 263 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2013 | 621 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 934 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 819 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2013 | 733 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 6437 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1226 | 0.020 |
Why?
| | Adolescent | 2 | 2022 | 17949 | 0.020 |
Why?
| | Phylogeny | 1 | 2013 | 802 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2013 | 437 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2793 | 0.020 |
Why?
| | Databases, Factual | 1 | 2013 | 1149 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 6266 | 0.020 |
Why?
| | Young Adult | 1 | 2022 | 10515 | 0.020 |
Why?
| | United States | 1 | 2021 | 12340 | 0.020 |
Why?
| | Animals | 1 | 2023 | 32120 | 0.010 |
Why?
|
|
Ahrendt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|